![Page 1: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/1.jpg)
PROSTATE CANCER SCREENING
• Dan O’Connell, MD
• Dept of Family Medicine
• 2/4/05
![Page 2: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/2.jpg)
MEN’S HEALTH AND DISPARITIES
• Higher income
• Dominate decision making roles in society
• 10 times more likely to commit DV
• Male MDs interupt more than female MDs
• Die 5-6 years sooner (74.4 vs 79.8)
• Do not seek out preventive medical care
![Page 3: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/3.jpg)
Cancer Morbidity/Mortality, 2001
• Incidence
• Lung 172,000 • Colo-rectal 184,000
• Breast 214,000
• Prostate 232,000• Pancreas 32,200• Melanoma 60,000
• Cervical 10,400
• Deaths
• Lung 163,000• Colo-rectal 56,000
• Breast 40,000
• Prostate 30,000• Pancreas 31,800• Melanoma 8,000
• Cervical 3,700
![Page 4: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/4.jpg)
Prostate CA facts
• 10% of men will have symptomatic disease in their lifetime
• 4% die from prostate cancer
![Page 5: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/5.jpg)
![Page 6: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/6.jpg)
![Page 7: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/7.jpg)
![Page 8: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/8.jpg)
![Page 9: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/9.jpg)
Spectrum of disease
• End stage prostate CA – bone mets to lumbar spine, very painful, urine, stool incontinence, possible paralysis
• Benign prostate CA –Microscopic, inconsequential, found in 30% autopsies, 70% over age 80
![Page 10: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/10.jpg)
PROSTATE CANCER- HETEROGENEITY
• Widely varying growth rates
• Widely varying potential to cause mortality
• Screening poorly differentiates clinically significant tumors from insignificant
![Page 11: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/11.jpg)
Case 1
• 61 yo man with HTN, DJD knees heard on the radio that he should get his PSA checked
• What do you advise?
![Page 12: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/12.jpg)
Case 2
• 44 yo African American notes his father died of prostate cancer at age 61
• He asks if he should be checked for this
![Page 13: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/13.jpg)
* For men in their 50s, about 50; for men in their 70s, about 270.† For men in their 50s, about 150; for men in their 70s, about 400.‡ For men in their 50s, about 17; for men in their 70s, about 90.§ For men in their 50s, about 30; for men in their 70s, about 100.¦ For men in their 50s, about 12; for men in their 70s, about 63.** For men in their 50s, about 21; for men in their 70s, about 70.
Yield of PSA, Men in their 60s
![Page 14: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/14.jpg)
Biopsies
• 4-6 biopsies obtained from different parts of glands, focusing on area of mass if found on DRE
• Sensitivity of biopsies (based on repeat biopsies) : 70-90%
![Page 15: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/15.jpg)
Gleason Score• Tumors graded 1-5 based on cells and
architecture
• How is the Gleason score calculated?
![Page 16: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/16.jpg)
Gleason Score• Tumors graded 1-5 based on cells and
architecture
• Primary and secondary
• Gleason 2-4 - well differentiated low grade
• Gleason 5-7 – Moderately Differentiated
• Gleason 8-10 – Poorly differentiated, high grade
![Page 17: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/17.jpg)
How is prostate cancer staged?
![Page 18: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/18.jpg)
Bone Scans
• PSA % positive bone scans
• <10 2.3%
• 10-19 5.3%
• 20-50 16.2%
• Recommended for PSA >10 or Gleason 7 or more
![Page 19: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/19.jpg)
CT scans
• For extra capsular tumors
• 244 men with PSA <15, Gleason 2-7, T2b or less: all had neg CT (Lee, Int J Radiat Oncol
Biol Phys, 12/00)
![Page 20: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/20.jpg)
Prostate Screening Guidelines American Cancer Society - 1993
• Annual DRE beginning at 40
• Annual PSA– beginning at 40 for
• African Americans
• Family history of prostate cancer
– beginning at 50 for all other menAmerican Cancer Society, 1993
![Page 21: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/21.jpg)
![Page 22: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/22.jpg)
Prostate Screening Guidelines American Urological Association-1995
• “Patients in these age/risk groups should be given information about these tests and should be given the option to participate”
![Page 23: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/23.jpg)
Prostate Screening Guidelines American Cancer Society - 2001
PSA and Digital Rectal Examination should be offered annually, beginning at age 50 years, to men who have at least a 10-year life expectancy .... Information should be provided to patients regarding potential risks and benefits of intervention.
American Cancer Society
![Page 24: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/24.jpg)
An Evidence TableAn Evidence Table
![Page 25: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/25.jpg)
PSA velocity
• For PSA between 2.5 and 4.0:
• “An increase of > 0.75 ng/ml per year may be 90% specific for CA (cancer) detection.”
![Page 26: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/26.jpg)
Age / PSA cut-off value (ng/ml)
• 40 - 49 / 2.5• 50 - 59 / 3.5• 60 - 69 / 4.5• 70 - 79 / 6.5
• If there is cancer: PSA increases 2.2 for every 1 gram of cancer
![Page 27: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/27.jpg)
External factors effecting PSA
• FALSE ELEVATION
• DRE• Prostatitis, • BPH• Urinary retention• Ejaculation within 48
hours
• FALSE DECREASE
• Finasteride (proscar)• Saw palmetto
![Page 28: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/28.jpg)
AAFP PSA Decision Aid Men in their 60s
http://www.aafp.org/clinical/tools/
![Page 29: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/29.jpg)
Sensitivity, Specificity, Pos Pred Value, Neg Pred Value
+
Prostate CA
No
Prostate CA
PSA >4 3
True +
7
False +
PSA <4 1
False -
89
True -
![Page 30: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/30.jpg)
Sens, Spec PPV, NPV
• Sensitivity = a/ (a+c) = 3/4 = 75%
• Specificity = d/(b+d) = 89/96 = 93%
• PPV = a/ (a+b) = 3/10 = 30%
• NPV = d/ (c+d) = 89/90 = 99%
![Page 31: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/31.jpg)
What are the possible disadvantages of having a PSA
test?
![Page 32: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/32.jpg)
![Page 33: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/33.jpg)
AAFP PSA Balance Sheet
http://www.aafp.org/clinical/tools/
![Page 34: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/34.jpg)
Cancer Morbidity/Mortality, 2001
• Incidence
• Lung 172,000 • Colo-rectal 184,000
• Breast 214,000
• Prostate 232,000• Pancreas 32,200• Melanoma 60,000
• Cervical 10,400
• Deaths
• Lung 163,000• Colo-rectal 56,000
• Breast 40,000
• Prostate 30,000• Pancreas 31,800• Melanoma 8,000
• Cervical 3,700
![Page 35: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/35.jpg)
AAFP PSA Balance Sheet
http://www.aafp.org/clinical/tools/
![Page 36: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/36.jpg)
Prostate Screening Harms AUA Guideline
www.guidelines.gov
![Page 37: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/37.jpg)
Prostate Screening Harms USPSTF Guideline
![Page 38: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/38.jpg)
Prostate Screening Harms ACS Guideline
![Page 39: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/39.jpg)
Summary of RecommendationsThe U.S. Preventive Services Task Force
(USPSTF)• www.ahrq.gov• The evidence is insufficient to recommend for or against
routine screening for prostate cancer using prostate specific antigen (PSA) testing or digital rectal examination (DRE). Rating:
• I recommendation.
• Rationale: The USPSTF found good evidence that PSA screening can detect early-stage prostate cancer but mixed and inconclusive evidence that early detection improves health outcomes. Screening is associated with important harms, including frequent false-positive results and unnecessary anxiety, biopsies, and potential complications of treatment of some cancers that may never have affected a patient's health. The USPSTF concludes that evidence is insufficient to determine whether the benefits outweigh the harms for a screened population.
![Page 40: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/40.jpg)
Strength of Recommendations
A. Good evidence to support
B. Fair evidence to support
C. No recommendation for or against.
D. Fair evidence to exclude
I. Insufficient Evidence to recommend for or against
![Page 41: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/41.jpg)
TREATMENT – RADICAL PROSTATECTOMY
• Treatment in 1/3 of all cases
• Treatment in 1/2 of cases in men <75
10 YEAR SURVIVAL
Radical prost.
Radiation therapy
Watchful waiting
Well diff 94 90 93
Mod diff 87 77 76
Poorly dif 67 53 45
Lu-Yao GL, Yao ,Lancet 1997;349:906-910.
![Page 42: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/42.jpg)
HARM
Men with ReducedSexual Function
Men withUrinary Problems
Men withBowel Problems
Men withOther Problems
Treatment
Radical Prostatectomy
20%-70% 15%-50% - -
External Beam Radiation Therapy
20%-45% 2%-16% 6%-25%
Brachytherapy (seeds)
36%2 6%-12%2 18%2
Androgen Deprivation Therapy(LHRH agonists)
40%-70% Breast Swelling: 5%-25%Hot Flashes: 50%-60%
![Page 43: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/43.jpg)
ANDROGEN DEPRIVATION THERAPY
• Bilateral Orchiectomy
• LHRH agonists (e.g., goserelin or leuprolide (Lupron))
![Page 44: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/44.jpg)
PSA SCREENING AT AGE 70
• 50% Life expectancy = 10 years
• Prostate CA with 90% 10 yr survival rate
• Less QALYs to be gained, higher harm, but also much higher number of cancers detected
![Page 45: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/45.jpg)
![Page 46: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/46.jpg)
ALTERNATIVE TO PSA
• early prostate cancer antigen (EPCA), a subset of PSA that appears only after the development of prostate tumors
• Genetic markers for Prostate CA
![Page 47: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/47.jpg)
PROSTATE CANCER –ASSOCIATED FACTORS
• Red meat
• High fat diet
• High dairy intake
• Fried and charcoal grilled meat
![Page 48: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/48.jpg)
PROSTATE CANCER PREVENTION
• Alpha-linolenic acid (ALA) (flax seed oil) (50% lower amongst lowest quintile vs top)
• EPA (Fish oil) – 11% less in top quintile (Leitzman Journal of Nutrition, 7/04)
• Selenium 0.12-0.19 ppm vs 0.06-0.09 ppm 50-70% less advanced DZ (Li, Journal of the NCI 5/04)
![Page 49: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/49.jpg)
PROSTATE CANCER PREVENTION – protective
factors• Soy (Gronberg, Lancet, 3/03)
• Tomato (lycopene) (Chen, Journal of the NCI 12/01)
• Vitamin E (Gronberg, Lancet, 3/03)
• Selenium (Brooks, Journal of Urology, 12/01)
• Sun Exposure (Luscombe, Lancet, 8/01)
• Vegetable intake (>28/wk vs <14/wk- 35% less dz) (Cohen, Journal of the NCI, 1/00)
![Page 50: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/50.jpg)
PROSTATE CANCER PREVENTION- NO EFFECT
• Smoking
• Alcohol
• Exercise
• Vasectomy
• Sexual activity
![Page 51: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/51.jpg)
Testosterone exposure?
• Marketing of testosterone for slowing aging in men is beginning, analogous to use of estrogen replacement (HRT) in women in the 1980s
• Effects of disease unknown
![Page 52: PROSTATE CANCER SCREENING Dan O’Connell, MD Dept of Family Medicine 2/4/05](https://reader035.vdocument.in/reader035/viewer/2022062421/56649f435503460f94c63b2e/html5/thumbnails/52.jpg)